Rallybio Corp (RLYB) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Rallybio Corp stock $10.58, price $15.75, that is 32.8% below the price, quality 57 out of 100. Rating: overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range $2.00 – $159.28 · fair‑value band $6.98 – $13.22 · the $15.75 price screens above the $10.58 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Rallybio in your weekly email
Every Wednesday you see whether Rallybio is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases.
Show moreShow less
Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.
The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia.
Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
Stock analysis
Rallybio Corp (RLYB) currently trades at $15.75, while our model-based Fair Value estimate is $10.58, 33% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $6.98 (bear) to $13.22 (bull), the price of $15.75 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Rallybio Corp reported revenue of $858K in FY2025 versus $0 in FY2021. Reported net income was −$9.0M in FY2025.
Key figures
Market cap $91.3M Micro · P/E ratio 3.4 · EPS (TTM) $4.61 · Return on equity 34.5% · Return on assets (EBIT) −53.0% (5-year average) · Operating margin −5,189% · Revenue (TTM) $434K · Free cash flow −$29.8M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 49 out of 100 (low confidence).
What moves the price
The share trades about 9% below its 52-week high and 264% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −33%, RLYB screens richer than that median.
Fair Value models
Bear$6.98Fair Value $10.58Bull$13.22
Price $15.75 · Downside -32.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($3.95 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, one officer or director sold shares worth $9,608 and none bought.
SaleJonathan I LieberChief Financial Officer2× since Feb 23, 2026: 1,388 shares, avg. $9.80$13,600Oct 27, 2026
BuyADAR1 Capital Management, LLC10% owner2× since May 11, 2026: 67,009 shares, avg. $13.99$937,630May 19, 2026
BuyDaniel Schneeberger10% owner2× since May 4, 2026: 235,464 shares, avg. $13.98$3.3MMay 15, 2026
Plus 18 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.51/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 6/7 measures
Overall it ranks above its industry peers.
Valuation
Quality Score57 · Above median
Fair Value upside−32.8% · Above median
Profitability
Return on equity (12 months)34.5% · Top 25%
Return on assets−14.4% · Below median
Growth and dividend
Revenue growth (quarter YoY)0.0% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (12 months)3.4× · Cheapest 25%
P/B1.58× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)100· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Rallybio Corp Fair Value". https://www.fairvalue-calculator.com/stock/RLYB
Frequently asked questions
Is Rallybio Corp (RLYB) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $10.58 versus a price of $15.75, about 33% lower (overvalued).
What is the fair value of RLYB?
Our model-based fair value for Rallybio Corp is $10.58 (as of Nov 8, 2026), built from audited fundamentals. The current price: $15.75.
What is the quality score of RLYB?
Rallybio Corp has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Rallybio Corp (RLYB)?
Our model-based price target is the fair value of $10.58 (as of Nov 8, 2026) from 1 valuation models. Cautious scenario $6.98, optimistic scenario $13.22. It is a calculation from audited fundamentals, not an analyst target.
What is the Rallybio Corp stock forecast for 2026?
Our models put fair value at $10.58, about 33% lower versus a price of $15.75 (overvalued). Cautious scenario $6.98, optimistic scenario $13.22. The calculation is refreshed regularly with new filings.
What is the revenue of Rallybio Corp (RLYB)?
Rallybio Corp reported trailing-twelve-month revenue of about $434K (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of Rallybio Corp (RLYB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Rallybio Corp it is $10.58 per share (as of Nov 8, 2026), against a price of $15.75. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Rallybio Corp stock overvalued or undervalued in 2026?
As of Nov 8, 2026, RLYB trades above its calculated fair value: price $15.75, fair value $10.58, a gap of about −33% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RLYB?
No. The price is what the market pays today ($15.75); the fair value is what the company's own numbers justify ($10.58). For Rallybio Corp the two are $5.17 per share apart. That gap is exactly why we show both numbers side by side.
How much is Rallybio Corp worth?
The market values Rallybio Corp at about $91.3M (market capitalisation, as of Nov 8, 2026). Per share that is $15.75; our models calculate a fair value of $10.58 per share.
What do the bullish and bearish scenarios say about RLYB?
Our models span a range for Rallybio Corp: cautious scenario $6.98, base $10.58, optimistic $13.22 per share (as of Nov 8, 2026, price $15.75). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of RLYB?
Rallybio Corp trades at a price-to-earnings ratio of 3.4 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $10.58 is built from several models across several years. Other multiples: P/B 1.6.
How solid is the balance sheet of Rallybio Corp (RLYB)?
Balance-sheet figures for Rallybio Corp (as of Nov 8, 2026): return on equity 34.5%. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is RLYB from its 52-week high?
Rallybio Corp trades at $15.75, about 9% below its 52-week high of $17.22 and 264% above the low of $4.33 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $10.58 is for.
Which stocks are comparable to Rallybio Corp?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Rallybio Corp stock attractive at the current price?
The data as of Nov 8, 2026: price $15.75, calculated fair value $10.58 (−33%), Quality Score 57/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RLYB calculated?
We run Rallybio Corp through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $10.58 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Rallybio Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Rallybio Corp (RLYB)?
The closing price on Nov 6, 2026 was $15.75. Our model-based fair value is $10.58, about 33% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Rallybio Corp right now?
The price sits above even our optimistic bull case ($13.22). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($6.98 to $13.22) leaves room in how you read the outcome.
Key figures of Rallybio Corp
How large is the market capitalisation of Rallybio Corp (RLYB)?
The market capitalisation of Rallybio Corp is $91.3M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Rallybio Corp (RLYB)?
Earnings per share at Rallybio Corp are $4.61 (price ÷ EPS = P/E 3.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Rallybio Corp (RLYB)?
The return on equity (ROE) of Rallybio Corp is 34.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Rallybio Corp (RLYB)?
On an EBIT basis the return on assets of Rallybio Corp is −53.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Rallybio Corp (RLYB)?
The operating margin of Rallybio Corp is −5,189% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Rallybio Corp (RLYB) generate?
The free cash flow of Rallybio Corp is −$29.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Rallybio Corp (RLYB) hold?
Rallybio Corp holds more cash than debt, $31.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Rallybio Corp in the live analysis
One click puts Rallybio Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026
